These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 23991142)
1. Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance. Billong SC; Fokam J; Aghokeng AF; Milenge P; Kembou E; Abessouguie I; Meva'a-Onglene FB; Bissek AC; Colizzi V; Mpoudi EN; Elat JB; Shiro KS PLoS One; 2013; 8(8):e72680. PubMed ID: 23991142 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study). Fokam J; Santoro MM; Takou D; Njom-Nlend AE; Ndombo PK; Kamgaing N; Kamta C; Essiane A; Sosso SM; Ndjolo A; Colizzi V; Perno CF BMC Pediatr; 2019 Jul; 19(1):226. PubMed ID: 31277610 [TBL] [Abstract][Full Text] [Related]
3. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon. Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487 [TBL] [Abstract][Full Text] [Related]
4. Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. Hong SY; Jonas A; DeKlerk M; Shiningavamwe A; Desta T; Badi A; Morris L; Hunt GM; Ledwaba J; Sheehan HB; Lau K; Trotter A; Tang AM; Wanke C; Jordan MR J Acquir Immune Defic Syndr; 2015 Apr; 68(4):463-71. PubMed ID: 25564107 [TBL] [Abstract][Full Text] [Related]
5. Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon. Meriki HD; Tufon KA; Anong DN; Atanga PN; Anyangwe IA; Cho-Ngwa F; Nkuo-Akenji T PLoS One; 2019; 14(11):e0225575. PubMed ID: 31751428 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Aghokeng AF; Vergne L; Mpoudi-Ngole E; Mbangue M; Deoudje N; Mokondji E; Nambei WS; Peyou-Ndi MM; Moka JJ; Delaporte E; Peeters M Antivir Ther; 2009; 14(3):401-11. PubMed ID: 19474474 [TBL] [Abstract][Full Text] [Related]
7. Comparisons of Primary HIV-1 Drug Resistance between Recent and Chronic HIV-1 Infection within a Sub-Regional Cohort of Asian Patients. Kiertiburanakul S; Chaiwarith R; Sirivichayakul S; Ditangco R; Jiamsakul A; Li PC; Kantipong P; Lee C; Ratanasuwan W; Kamarulzaman A; Sohn AH; Sungkanuparph S; PLoS One; 2013; 8(6):e62057. PubMed ID: 23826076 [TBL] [Abstract][Full Text] [Related]
9. Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda. Kaleebu P; Kirungi W; Watera C; Asio J; Lyagoba F; Lutalo T; Kapaata AA; Nanyonga F; Parry CM; Magambo B; Nazziwa J; Nannyonjo M; Hughes P; Hladik W; Ruberantwari A; Namuwenge N; Musinguzi J; Downing R; Katongole-Mbidde E; PLoS One; 2015; 10(12):e0145536. PubMed ID: 26700639 [TBL] [Abstract][Full Text] [Related]
10. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016. Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167 [TBL] [Abstract][Full Text] [Related]
11. Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings. Fokam J; Billong SC; Bissek AC; Kembou E; Milenge P; Abessouguie I; Nkwescheu AS; Tsomo Z; Aghokeng AF; Ngute GD; Ndumbe PM; Colizzi V; Elat JB BMC Public Health; 2013 Apr; 13():308. PubMed ID: 23565992 [TBL] [Abstract][Full Text] [Related]
12. Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study. Kan W; Teng T; Liang S; Ma Y; Tang H; Zuohela T; Sun G; He C; Wall KM; Marconi VC; Liao L; Leng X; Liu P; Ruan Y; Xing H; Shao Y BMJ Open; 2017 Sep; 7(9):e016012. PubMed ID: 28882911 [TBL] [Abstract][Full Text] [Related]
13. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188 [TBL] [Abstract][Full Text] [Related]
14. Short Communication: Population-Based Surveillance of HIV-1 Drug Resistance in Cameroonian Adults Initiating Antiretroviral Therapy According to the World Health Organization Guidelines. Fokam J; Takou D; Santoro MM; Akonie HZ; Kouanfack C; Ceccherini-Silberstein F; Colizzi V; Perno CF; Ndjolo A AIDS Res Hum Retroviruses; 2016 Apr; 32(4):329-33. PubMed ID: 26602836 [TBL] [Abstract][Full Text] [Related]
15. HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam. Thao VP; Le T; Török EM; Yen NT; Chau TT; Jurriaans S; van Doorn HR; de Jong MD; Farrar JJ; Dunstan SJ Antivir Ther; 2012; 17(5):905-13. PubMed ID: 22473024 [TBL] [Abstract][Full Text] [Related]
16. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon. Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858 [TBL] [Abstract][Full Text] [Related]
17. Utilization of dried blood spot specimens can expedite nationwide surveillance of HIV drug resistance in resource-limited settings. Zhang G; DeVos J; Medina-Moreno S; Wagar N; Diallo K; Beard RS; Zheng DP; Mwachari C; Riwa C; Jullu B; Wangari NE; Kibona MS; Ng'Ang'A LW; Raizes E; Yang C PLoS One; 2018; 13(9):e0203296. PubMed ID: 30192818 [TBL] [Abstract][Full Text] [Related]
18. Early warning indicators for HIV drug resistance in Cameroon during the year 2010. Billong SC; Fokam J; Nkwescheu AS; Kembou E; Milenge P; Tsomo Z; Dion GN; Aghokeng AF; Mpoudi EN; Ndumbe PM; Colizzi V; Elat Nfetam JB PLoS One; 2012; 7(5):e36777. PubMed ID: 22615810 [TBL] [Abstract][Full Text] [Related]
19. HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study. Coetzee J; Hunt G; Jaffer M; Otwombe K; Scott L; Bongwe A; Ledwaba J; Molema S; Jewkes R; Gray GE PLoS One; 2017; 12(12):e0188606. PubMed ID: 29244809 [TBL] [Abstract][Full Text] [Related]
20. Predictors of poor retention on antiretroviral therapy as a major HIV drug resistance early warning indicator in Cameroon: results from a nationwide systematic random sampling. Billong SC; Fokam J; Penda CI; Amadou S; Kob DS; Billong EJ; Colizzi V; Ndjolo A; Bisseck AZ; Elat JN BMC Infect Dis; 2016 Nov; 16(1):678. PubMed ID: 27846809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]